
Diabetes Dialogue: OPTIMAL-DIABETES, Survodutide, and Orforglipron at AHA 2026
Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives !
Late-breaking data from the
On a recent episode of Diabetes Dialogue, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, reviewed OPTIMAL-DIABETES, SYNCHRONIZE-CVOT, and ATTAIN-OSA and their implications for cardiometabolic care.
OPTIMAL-DIABETES randomized nearly 9500 adults aged 50 years and older with
The neutral result contrasts with BPROAD, a Chinese trial in which stroke reduction drove benefit from a target of <120 mm Hg. A target of <130/80 mm Hg likely remains reasonable for most patients, with lower goals individualized against dizziness, falls, electrolyte disturbances, and frailty.
Survodutide, an investigational glucagon and glucagon-like peptide-1 (GLP-1) receptor dual agonist, met noninferiority for 5-point major adverse cardiovascular events in SYNCHRONIZE-CVOT. Among 5530 adults with a BMI of ≥27 kg/m² and cardiovascular disease or multiple risk factors, the primary endpoint occurred in 3.7% vs 4.1% with placebo (hazard ratio, 0.89). The CI crossed 1, and a median follow-up near 22 months limited any test of superiority.2
Adverse events affected 93% of participants receiving 3.6 mg or 6 mg doses vs 85.6% with placebo. Gastrointestinal events leading to discontinuation separated the groups sharply, at 19.3% and 20.8% vs 1.9%, raising questions about titration.
In ATTAIN-OSA, once-daily oral orforglipron (Foundayo) reduced the apnea-hypopnea index at 52 weeks by 17.8 vs 4.5 events per hour without positive airway pressure (PAP) and by 17.3 vs 5.3 events per hour with PAP. Tirzepatide (Zepbound) already holds an OSA indication, but an oral option could reach patients averse to injections. Whether benefit extends beyond weight loss, and whether a small-molecule GLP-1 receptor agonist matches peptide cardiovascular outcomes, remains unresolved.3
Collectively, the trials point toward individualized blood pressure goals in diabetes and a rising evidentiary bar for incretin-based therapies, where cardiovascular benefit, tolerability, and active-comparator data will increasingly shape agent selection.
Editors’ Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.
References
Santo K, Martins E, Silva GS, et al. Intensive Blood-Pressure Lowering in Patients with Type 2 Diabetes. N Engl J Med. 2026 Nov 7.
doi: 10.1056/NEJMoa2612922 Bozkurt B, le Roux CW, Wharton S, et al. Cardiovascular outcomes with Survodutide in adults with obesity at increased cardiovascular risk (synchronize-CVOT): A double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet. Published online November 9, 2026.
doi:10.1016/s0140-6736(26)02140-9 Malhotra A, Gottlieb DJ, Woehrle H, et al. Orforglipron for obstructive sleep apnea. JAMA. Published online November 9, 2026.
doi:10.1001/jama.2026.24080
Related to this article








